Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
InFo Hämatologie + Onkologie
Erschienen in: InFo Hämatologie + Onkologie 7/2017

02.11.2017 | Brachytherapie | zertifizierte fortbildung

Fortschritte der Radioonkologie

Aktueller Stand in der Behandlung von Tumoren der Kopf-Hals-Region

verfasst von: Prof. Dr. med. Rainer Fietkau

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Strahlentherapie ist wichtiger Teil der Behandlung von Kopf-Hals-Tumoren. Verschiedene technische Fortschritte erlauben heute bereits eine nebenwirkungsärmere Bestrahlung. Die Deeskalation der Behandlung für ausgesuchte Patienten sowie die Kombinationstherapie mit Antikörpern und Immuntherapeutika gehören zu den aktuellen und zukünftigen Herausforderungen.
Literatur
1.
Marta GN et al. Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol. 2014;110(1):9–15.CrossRefPubMed
2.
3.
4.
Adelstein D et al. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw. 2017;15(6):761–770.CrossRefPubMed
5.
Pignon JP et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.CrossRefPubMed
6.
Jerzak KJ et al. A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN). Oral Oncol. 2017;71:1–10.CrossRefPubMed
7.
Budach W et al. Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials. Radiother Oncol. 2016;118(2):238–43.CrossRefPubMed
8.
Stromberger C et al. Unilateral and bilateral neck SIB for head and neck cancer patients: Intensity-modulated proton therapy, tomotherapy, and RapidArc. Strahlenther Onkol. 2016;192(4):232–9.CrossRefPubMed
9.
Trifiletti DM et al. Beyond Positive Margins and Extracapsular Extension: Evaluating the Utilization and Clinical Impact of Postoperative Chemoradiotherapy in Resected Locally Advanced Head and Neck Cancer. J Clin Oncol. 2017;35(14):1550–60.CrossRefPubMed
10.
Maxwell JH et al. Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer. 2013;119(18):3302–8.CrossRefPubMed
11.
Al-Mamgani A et al. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2017;274(10): 3757–65.CrossRef
12.
Chang CL et al. High-dose or low-dose cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer. Head Neck. 2017;39(7):1364–70.CrossRefPubMed
13.
Rades D et al. Comparing two lower-dose cisplatin programs for radio-chemotherapy of locally advanced head-and-neck cancers. Eur Arch Otorhinolaryngol. 2017;274(2):1021–27.CrossRefPubMed
14.
Rades D et al. Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. J Craniomaxillofac Surg. 2016;44(9):1436–40.CrossRefPubMed
15.
Liang H et al. Comparison of Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with local-regionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial. J Clin Oncol. 2017; 35(Suppl);Abstr 6006.
16.
Noronha V et al. W3W Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer. J Clin Oncol. 2017;35(Suppl);Abstr 6007.
17.
Rodriguez CP et al. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design. Head Neck. 2015;37(11):1583–9.CrossRefPubMed
18.
Giralt J et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
19.
Magrini SM et al. Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. J Clin Oncol. 2016;34(5):427–35.CrossRefPubMed
20.
Siu LL et al. Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. JAMA Oncol. 2017;3(2):220–226.CrossRef
21.
Lacas B et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221–37.CrossRefPubMed
22.
Blanchard P et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol. 2013;31(23):2854–60.CrossRefPubMed
23.
Watkins JM et al. Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancers. Head Neck. 2009;31(4):493–502.CrossRefPubMed
24.
Salama JK et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006;64(2):382–91.CrossRefPubMed
25.
Tortochaux J et al. Randomized phase III trial (GORTEC 98-03) comparing re-irradiation plus chemotherapy versus methotrexate in patients with recurrent or a second primary head and neck squamous cell carcinoma, treated with a palliative intent. Radiother Oncol. 2011;100(1):70–5.CrossRefPubMed
26.
Duprez F et al. Intensity-modulated radiotherapy for recurrent and second primary head and neck cancer in previously irradiated territory. Radiother Oncol. 2009;93(3):563–9.CrossRefPubMed
27.
Sulman EP et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009;73(2):399–409.CrossRefPubMed
28.
Lee N et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;68(3):731–40.CrossRefPubMed
29.
Dornoff N et al. Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2015;191(8):656–64.CrossRefPubMed
30.
Langer CJ et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007;25(30):4800–5.CrossRefPubMed
31.
Semrau S et al. Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: what are the best predictors of remission and prognosis? Cancer. 2015;121(8):1214–22.CrossRefPubMed
32.
Wichmann G et al. Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET/CT. Eur J Cancer. 2017;72:144–155.CrossRefPubMed
33.
Strojan P et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head Neck. 2016;38 Suppl 1:E2151–8.CrossRefPubMed
34.
Guan J et al. A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). Oncotarget. 2016;7(6):7110–19.CrossRefPubMedPubMedCentral
35.
Budach V et al. Five years’ results of the German ARO 04-01 trial of concurrent 72 Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer. J Clin Oncol. 2012;30(Suppl);Abstr 5512.
36.
Strnad V et al. Reirradiation for recurrent head and neck cancer with salvage interstitial pulsed-dose-rate brachytherapy: Long-term results. Strahlenther Onkol. 2015;191(6):495–500.CrossRefPubMed
37.
Vermorken JB et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.CrossRefPubMed
38.
Knoedler M et al. Cetuximab (C), fluorouracil (F) and cisplatin (P) alone or with docetaxel (D) for recurrent/metastatic (RM) head and neck cancer (HNSCC). Final Analysis of AIO Trial # 1108 - CEFCID. Ann Oncol. 2014;25(4, Suppl);Abstr. 987O.
39.
Joshi A et al. Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer. J Clin Oncol. 2017;35(15, Suppl);Abstr. 6018.
40.
Ferris RL et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375(19):1856–67.CrossRefPubMed
Metadaten
Titel
Fortschritte der Radioonkologie
Aktueller Stand in der Behandlung von Tumoren der Kopf-Hals-Region
verfasst von
Prof. Dr. med. Rainer Fietkau
Publikationsdatum
02.11.2017
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 7/2017
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-017-5564-4

Weitere Artikel der Ausgabe 7/2017

InFo Hämatologie + Onkologie 7/2017 Zur Ausgabe

journal club

ALK-Inhibitoren im Head-to-Head-Vergleich

neues aus der forschung

Beobachten ist eine Alternative

kurz notiert

Das Mikrobiom im Fokus der Immunonkologen

infopharm

Entzündungshemmer gegen Lungenkrebs?

journal club

Höhere Strahlendosis steigert Kardiotoxizität beim Mammakarzinom

infopharm

NSCLC/Urothelkarzinom: PD-L1-Inhibitor zugelassen

Weitere Lesetipps

Systemtherapie des Prostatakarzinoms im hohen Alter

ANZEIGE

Dexpanthenol verstärkt die positiven Effekte der LASH-Methode

ANZEIGE

Neue Konzepte beim Handekzem

Arteriosklerose noch normal?

ANZEIGE

Im Dialog mit jungen Dermatologen: Wund- und Narbenversorgung in der Praxis

Hochintensiver fokussierter Ultraschall zur Hautstraffung

Bildnachweise